Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 26;8(7):12484–12500. doi: 10.18632/oncotarget.14226

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2017 Leão et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

A. Percentage of clinical trials employing each types of epigenetic therapeutic agents in prostate cancer; B. Percentage of clinical trials using mono or combined therapy as therapeutic strategy with the different classes of epigenetic drugs in prostate cancer; C. Percentage of clinical trials where different agents are used in combined therapies for prostate cancer; D. Percentage of clinical trials employing each types of epigenetic therapeutic agents in kidney cancer; E. Percentage of clinical trials using mono or combined therapy as therapeutic strategy with the different classes of epigenetic drugs in kidney cancer; F. Percentage of clinical trials where different agents are used in combined therapies for kidney cancer G. Percentage of clinical trials employing each types of epigenetic therapeutic agents in bladder cancer; H. Percentage of clinical trials using mono or combined therapy as therapeutic strategy with the different classes of epigenetic drugs in bladder cancer; I. Percentage of clinical trials where different agents are used in combined therapies for bladder cancer